... WhatsApp

New Treatment Option for Advanced Pancreatic Cancer May Improve Survival Without Harming Quality of Life

You are here >> Home > Latest Updates > Pancreas Cancer Updates > New Treatment…

New Treatment Option for Advanced Pancreatic Cancer May Improve Survival Without Harming Quality of Life

Pancreatic cancer is one of the most difficult cancers to treat, especially when it has spread (metastatic disease). Two common first-line treatments are gemcitabine plus nab-paclitaxel (Gem + NabP) and a newer combination called NALIRIFOX, which includes liposomal irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin.

Earlier results from the large NAPOLI 3 trial showed that patients treated with NALIRIFOX lived longer and had more time before their cancer worsened compared to those who received Gem + NabP.

This new analysis focused on quality of life and physical function during treatment. Over 470 patients reported how they felt during therapy, using questionnaires that measured fatigue, pain, daily function, and overall well-being.

The results showed:
– Both groups had a slight drop in quality of life during the first 12 weeks, but this stabilized afterward.
– Patients on NALIRIFOX had a longer time before their health and physical ability declined compared with those on Gem + NabP.
– Importantly, the survival benefits of NALIRIFOX did not come at the cost of worse day-to-day functioning.

This means that for people with metastatic pancreatic cancer, NALIRIFOX may offer both longer survival and maintained quality of life, making it an important treatment option to discuss with doctors.

Rate this post

Exclusive Health Tips and Updates

Dr Harsh Shah - GI & HPB Oncosurgeon in Ahmeadbad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.